3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Sarcoma
2
Small Cell Lung Carcinoma
1
Myeloproliferative Disorders
1
Myelodysplastic Syndromes
1
Mycosis Fungoides
1
Multiple Myeloma
1
Melanoma
1
Lymphoma, T-Cell, Peripheral
1
Lymphoma, T-Cell, Cutaneous
1
Lymphoma, T-Cell
1
Lymphoma
1
Liposarcoma
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Leiomyosarcoma
1
Hodgkin Disease
1
Hematologic Neoplasms
1
Hemangiosarcoma
1
Dermatofibrosarcoma
1
Carcinoma, Squamous Cell
1
Carcinoma, Merkel Cell
1
Breast Neoplasms
1
Interventions
Trabectedin
2
Doxorubicin
2
sodium thiosulfate
1
plitidepsin
1
milademetan
1
avelumab
1
atezolizumab
1
X-Rays
1
TTI-621
1
Specimen Handling
1
Reverse Transcriptase Polymerase Chain Reaction
1
Platinum
1
Nelfinavir
1
Magnetic Resonance Spectroscopy
1
Immunoenzyme Techniques
1
Hyperthermic Intraperitoneal Chemotherapy
1
Gene Expression Profiling
1
Cytoreduction Surgical Procedures
1
Cyproheptadine
1
Cisplatin
1
Blotting, Western
1
Biopsy
1
1,2-diaminocyclohexaneplatinum II citrate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Liposarcoma
×
TTI-621
×
Clear all
NCT04996004
2024-12-11
TTI-621-03
Pfizer
Phase 2
Terminated
76 enrolled
53 charts